Xvivo Perfusion ABXVIPF -1.32%91 Current Ratio is 4.52 as of Mar. 2026, which is 17% below its 10-year median of 5.45. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 73.89% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Xvivo Perfusion AB's current ratio for the quarter that ended in Mar. 2026 was 4.52.
Xvivo Perfusion AB has a current ratio of 4.52. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Xvivo Perfusion AB's Current Ratio or its related term are showing as below:
XVIPF'
s Current Ratio Range Over the Past 10 Years
Min: 3.23 Med: 5.45 Max: 10.67
Current: 4.52
During the past 13 years, Xvivo Perfusion AB's highest Current Ratio was 10.67. The lowest was 3.23. And the median was 5.45.
XVIPF's Current Ratio is ranked better than 73.89% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs XVIPF: 4.52
Xvivo Perfusion AB (OTCPK:XVIPF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Xvivo Perfusion AB Current Ratio Related Terms
Xvivo Perfusion AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Current Ratio of 4.52 as of Mar. 2026. This is 17% below median its historical median of 5.45. Over the past decade, Xvivo Perfusion AB's Current Ratio has ranged from 3.23 to 10.67. According to the industry distribution chart, Xvivo Perfusion AB ranks #223 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 26.1%.
Is Xvivo Perfusion AB's Current Ratio too high?
Xvivo Perfusion AB's current Current Ratio of 4.52 is 17% below median its 10-year median of 5.45. Over the past 10 years, this metric has ranged from a low of 3.23 to a high of 10.67. The Medical Devices & Instruments industry median Current Ratio is 2.49. Xvivo Perfusion AB's value of 4.52 is 81.9% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #223 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #223 out of 854 companies for Current Ratio. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Current Ratio is 2.49. Xvivo Perfusion AB's value of 4.52 is 81.9% above this benchmark. Historically, Xvivo Perfusion AB's own Current Ratio has ranged from 3.23 to 10.67 over the past decade. While the company's 10-year median is 5.45 vs. the industry median of 2.49, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Current Ratio of 4.52 is 81.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Current Ratio is 4.52, which is 17% below median its own 10-year median of 5.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Current Ratio is 4.52, which is 17% below median its 10-year median of 5.45 and 81.9% above the Medical Devices & Instruments industry median of 2.49. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Current Ratio is 4.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Current Ratio: 4.52 (17% below median its 10-year median of 5.45)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 81.9% above the Medical Devices & Instruments median (#223 of 854)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
